A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome

Internal Medicine

Volumn 52, Issue 4, 2013, Pages 419-424

  Chao, Guan qun ^a   Zhang, Shuo ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Amitriptyline; Irritable bowel syndrome; Meta analysis

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; NORTRIPTYLINE; PLACEBO;

ABDOMINAL PAIN; ANTICHOLINERGIC EFFECT; ARTICLE; CONSTIPATION; DEFECATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROSTIMULATION; FLATULENCE; GASTROINTESTINAL TRANSIT; HUMAN; HYPERSENSITIVITY; IRRITABLE COLON; META ANALYSIS; PAIN; PAIN THRESHOLD; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

AMITRIPTYLINE; HUMANS; IRRITABLE BOWEL SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84873954321     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9147     Document Type: Article

References (33)

1. Chang L. Review article: epidemiology and quality of life in func-tional gastrointestinal disorders. Aliment Pharmacol Ther 20: 31-39, 2004.
2. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syn-drome, health care use, and costs: a U.S. managed care perspec-tive. Am J Gastroenterology 98: 600-607, 2003.
3. Sandler RS, Everhart JE, Donowitz M, et al. The burden of se-lected digestive diseases in the United States. Gastroenterology 122: 1500-1511, 2002.
4. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity facts, speculations, and challenges. Gut 48: 125-131, 2001.
5. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake in-hibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Arch Med Sci 4: 71-76, 2008.
6. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 30: 884-901, 2008.
7. Fumi AL, Trexler K. Rifaximin treatment for symptoms of irrita-ble bowel syndrome. Ann Pharmacother 42: 408-412, 2008.
8. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Effi-cacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51: 1775-1780, 2008.
9. Camilleri M. Management of the irritable bowel syndrome. Gas-troenterology 120: 652-668, 2001.
10. Clouse RE. Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial. Gastroenterol-ogy 125: 249-253, 2003.
11. Creed F, Ratcliffe J, Fernandez L, et al; North of England IBS Re-search Group. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic dis-orders. Br J Psychiatry 186: 507-515, 2005.
12. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 15: 1548-1553, 2009.
13. Jadad A. Randomised Controlled Trials: A User's Guide. BMJ Books, London, 1998.
14. Begg CB, Mazumdar M. Operating characteristics of a rank corre-lation test for publication bias. Biometrics 50: 1088-1101, 1994.
15. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634, 1997.
16. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitryptiline on symptoms, sleep and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 93: 160-165, 1998.
17. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitrip-tyline reduces rectal pain related activation of the anterior cingu-late cortex in patients with irritable bowel syndrome. Gut 54: 601-607, 2005.
18. Rajagopalan M, Kurian G, John J. Symptom relief with amitrip-tyline in the irritable bowel syndrome. J Gastroenterol Hepatol 13: 738-741, 1998.
19. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 27: 678-684, 2008.
20. Drossman DA, Dumitrascu DL. Rome III: new standard for func-tional gastrointestinal disorders. J Gastrointestin Liver Dis 15: 237-241, 2006.
21. Leong SA, Barghout V, Birnbaum HG, et al. The economic conse-quences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 163: 929-935, 2003.
22. Videlock EJ, Chang L. Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment. Gastroenterol Clin North Am 36: 665-685, 2007.
23. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gas-troenterol Clin North Am 40: 11-19, 2011.
24. Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karama-nolis DG. Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog b2: 3, 2010.
25. Hulisz D. The burden of illness of irritable bowel syndrome: cur-rent challenges and hope for the future. J Manag Care Pharm 10: 299-309, 2004.
26. Shen YH, Nahas R. Complementary and alternative medicine for treatment of irritable bowel syndrome. Can Fam Physician 55: 143-148, 2009.
27. Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ 332: 280-283, 2006.
28. Truong TT, Naliboff BD, Chang L. Novel techniques to study vis-ceral hypersensitivity in irritable bowel syndrome. Curr Gastroen-terol Rep 10: 369-378, 2008.
29. Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal dis-ease. Aliment Pharmacol Ther 24: 919-933, 2006.
30. Jackson JL, O'Malley PG, Tompkins G, Balden E, Santoro J, Kru-enke K. Treatment of functional gastrointestinal disorders with an-tidepressant medications: a meta-analysis. Am J Med 108: 65-72, 2000.
31. Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irrita-ble bowel syndrome in adolescents. J Pediatr 152: 685-689, 2008.
32. Thoua NM, Murray CD, Winchester WJ, et al. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Aliment Pharmacol Ther 29: 552-560, 2009.
33. Forootan H, Taheri A, Hooshangi H, Mohammadi HR. Effects of fluoxetine, nortriptyline and amitriptyline in IBS patients. Feyz Kashan Univ Med Sci Health Serv 21: 49-55, 2002.